Top Page
Sareum Holdings
(LSE:SAR)
Sareum Holdings (SAR) vs. S&P 500 (SPY)
Sareum Holdings Business Overview & Revenue Model
Sareum Holdings Financial Statement Overview
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 0.00 | 0.00 | 0.00 | 47.20K | Gross Profit |
| -1.00K | -1.00K | -2.00K | -1.09K | 47.20K | EBIT |
| -4.63M | -4.02M | -2.58M | -1.72M | -1.12M | EBITDA |
| -4.54M | -4.01M | -2.57M | -1.70M | -1.09M | Net Income Common Stockholders |
| -3.42M | -3.19M | -2.17M | -1.50M | -985.91K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 1.46M | 994.00K | 4.26M | 2.69M | 1.80M | Total Assets |
| 2.77M | 2.02M | 4.79M | 3.08M | 2.00M | Total Debt |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Net Debt |
| -1.46M | -994.00K | -4.26M | -2.69M | -1.80M | Total Liabilities |
| 653.00K | 867.00K | 455.00K | 284.15K | 198.54K | Stockholders Equity |
| 2.11M | 1.15M | 4.33M | 2.80M | 1.80M |
| Cash Flow | Free Cash Flow | |||
| -3.92M | -3.27M | -2.13M | -1.57M | -816.35K | Operating Cash Flow |
| -3.89M | -3.27M | -2.13M | -1.57M | -813.09K | Investing Cash Flow |
| -23.00K | -41.00K | -2.00K | -37.86K | 1.29K | Financing Cash Flow |
| 4.38M | 0.00 | 3.71M | 2.49M | 1.70M |
Sareum Holdings Technical Analysis
Sareum Holdings Peers Comparison
Sareum Holdings Corporate Events
Sareum Holdings has provided an update on its TYK2/JAK1 and SRA737 programs, highlighting significant progress in its preclinical studies for CNS indications and regaining full control of the SRA737 cancer treatment program. The company is considering strategic options for SRA737, including re-licensing or advancing it in-house, while continuing to develop its lead autoimmune and oncology programs, SDC-1801 and SDC-1802. These developments position Sareum to enhance shareholder value and strengthen its pipeline.
Spark’s Take on GB:SAR Stock
According to Spark, TipRanks’ AI Analyst, GB:SAR is a Underperform.
Sareum Holdings presents high financial risk with zero revenue and ongoing losses. While recent corporate events and strategic advancements offer some optimism, the financial and valuation challenges weigh heavily on the stock’s attractiveness.
To see Spark’s full report on GB:SAR stock, click here.
Sareum Holdings PLC announced the exercise of warrants for 924,242 new ordinary shares, raising £115,530.25. This move increases the total number of shares to 134,411,893, aligning with the company’s strategic focus on expanding its capital base to support ongoing development projects in autoimmune and cancer therapies.
Spark’s Take on GB:SAR Stock
According to Spark, TipRanks’ AI Analyst, GB:SAR is a Neutral.
Sareum Holdings’ financial challenges, including zero revenue and persistent losses, are significant headwinds. Technical indicators show mixed signals, and the valuation is unattractive due to negative earnings. However, positive corporate events and strategic advancements offer some optimism for future growth.
To see Spark’s full report on GB:SAR stock, click here.
Sareum Holdings PLC announced that its Executive Chairman, Dr. Stephen Parker, purchased 84,033 ordinary shares at an average price of 11.9 pence per share, increasing his total direct and indirect holdings to 405,045 shares, which represents approximately 0.30% of the company’s issued share capital. This transaction, conducted on the London Stock Exchange, reflects Dr. Parker’s confidence in the company’s strategic direction and potential growth, potentially influencing investor sentiment positively.
Sareum Holdings PLC reported significant progress in its half-year results for the period ending December 2024, marked by the successful completion of a Phase 1 clinical trial for its lead candidate, SDC-1801, which showed promising safety and pharmacokinetic profiles for treating autoimmune diseases. The company also strengthened its patent portfolio and acquired the license for SRA737 on improved economic terms, enhancing its pipeline and positioning in the biotechnology sector. Financially, Sareum raised £1.07m post-period, bolstering its resources to advance its therapeutic candidates, with a focus on addressing unmet needs in autoimmune and cancer treatments.
Sareum Holdings PLC will release its unaudited half-year results for the period ending 31 December 2024 on 25 March 2025. The company will also host a live investor presentation on the same day, open to current and potential shareholders. This event provides an opportunity for stakeholders to engage with the company’s progress and future plans, potentially impacting investor confidence and market positioning.
Sareum Holdings PLC has successfully raised £1.07 million through an institutional equity fundraise by issuing 8,560,000 new ordinary shares at a price of 12.5 pence each, which is a 24% discount to the previous day’s closing price. The funds will be used to support the development of Sareum’s expanded portfolio, including SRA737, and for general working capital, potentially enhancing the company’s market position and shareholder value.
Sareum Holdings has acquired the licence for SRA737, a clinical-stage oral Checkpoint kinase 1 inhibitor targeting cancer cell replication and DNA damage repair. This acquisition follows the programme’s return from a US-based biopharma company, with Sareum now securing a 63.5% share of future revenues. The move strengthens Sareum’s position to explore partnerships or development opportunities for SRA737, while ongoing costs will be limited to material and data storage, and intellectual property management. Sareum is also advancing its lead programme, SDC-1801, which has shown promising results in treating autoimmune diseases.